Skip to main content
OpenTrials
Completed

NCT Number: NCT03940547

Mycotoxin Mitigation Trial

Multiple observational studies show an association between fetal and post-natal aflatoxin exposure and reduced linear growth. However, the effects of confounding factors such as socio-economic status, food insecurity and nutrient deficiencies due to monotonous diets have not been ruled out. This trial will quantify the causal role of infant aflatoxin ingestion on post-natal growth by performing a cluster randomized trial in children 6-18 months of age in the Dodoma Region of Tanzania.

All health facilities in one district in Dodoma will be randomized to the control or intervention arm. Infants will be recruited into the study over one year to account for seasonal variation in AF exposure. Both arms will receive infant and young child feeding education, a thermos flask and plastic measuring scoops. The intervention arm will receive a low-aflatoxin pre-blended porridge flour containing maize and groundnut (ratio 4:1 respectively) and low-aflatoxin groundnut flour, whereas in the control arm the same porridge mix will be promoted through education, but acquired by the household. The primary outcome is length-for-age Z-score at 18 months.

Completed

Looking for future studies?

Notify Me

Key information

Age range

6 week–3 month

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Kongwa District Hospital

Kongwa, Dodoma, Tanzania

About this study

The objective of this study is to determine the effect of a very low AF complementary feeding intervention on LAZ using a cluster randomized design (CRT), while promoting a nutritionally adequate diet to all infants between 6-18 months of age. The hypothesis is that ingestion of AF can reduce infant length and that a reduction of AF exposure will result in improved length for age z-scores (LAZ). The primary outcome is LAZ, which will be measured at 18 months.

The unit of randomization is government-run health facilities (health centers, dispensaries and hospital, 52 clusters in total) in the Kongwa District. Mothers and infants will be recruited into the trial based on 42 day EPI visit attendance, which has very high (>95%) coverage in Kongwa District. Recruitment of infants will be performed for one complete calendar year capture variability in exposure by season.

Critical to casual inference is the intervention's ability to create a contrast of AF consumption between the control and intervention groups, without creating differential macro- or micro-nutrient intake or differences in feeding and care practices that could affect stunting between arms. To reduce the risk of introducing these biases, the investigators designed the intervention to include: 1) education to improve infant feeding and care practices in both arms, and 2) behavior change communication on the use of blended infant porridge flours in both arms. Participants in the intervention group will receive low-aflatoxin blended infant porridge flour and groundnut flour, made in accordance with Tanzanian food and mycotoxin regulations. Those in the control group will not receive any flour, but will be advised to feed their infants a blend similar in ingredients and ratio to what the intervention group will receive. Both groups will receive a thermos flask to store porridge and a small plastic measuring scoop to measure porridge flour for preparation of the porridge.

The sample size was calculated using a one-sided test of independent sample means, with a standard deviation of 1.2 Z, type I error of 0.05, power of 0.90, design effect of 2.0 and assuming a coefficient of variation of .144 for varying cluster size, based on previous year's data for EPI attendance at 42 days. Given these parameters our total sample size is calculated to be 2,322 (1,161 infants per cluster). Conservatively estimating a 20% loss to follow-up and infant mortality, the total number of infants is 2,787, or 54 infants recruited per health cluster annually or 4.5 infants per cluster per month. Rounding up, 5 infants per cluster each month will be recruited for a total of 3,120 potential infants, recognizing that in approximately 6 of the health facilities, it is unlikely that all 60 infants because of the size of the population served by the facility.

The trial will be conducted in the Kongwa District of Dodoma, Tanzania, where the investigators have performed formative research (Protocol Identification#: 1703007043) and confirmed AF contamination in local foods, primarily groundnuts, and that infants are exposed to aflatoxin. The frequency and level of exposure is similar in range to the West African observational studies. Kongwa District is a good location to perform this study, as exposure is high enough to be suspected of contributing to stunting, but low enough as to not cause aflatoxicosis.

NOTE: Data collection was stopped between April 9 and June 8, 2020 due to the SARS-CoV-2 outbreak, in accordance with the guidance of the Tanzanian National Institute for Medical Research. The delivery of the intervention continued during this time.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Babies >6 weeks old and <4 months old, who seek Expanded Program on Immunization (EPI) from a randomized health facility and reside in Kongwa District

Exclusion criteria

, assessed at recruitment and again at the 6-month visit:

  • Babies with disabilities that preclude normal feeding and swallowing
  • Refusal to consent to assigned intervention
  • An infant who has shown signs of a potential groundnut allergy (assessed the first time mother reports groundnut consumption)
  • An infant who is a twin
  • If the mother plans to travel for more than 2 months at or after the randomized intervention begins
  • If the mother is below 16 years of age

Treatment and study plan

Provision of flour

Other

Infant and young child feeding education and provision of low AF porridge and groundnut flours from 6-18 months

Promotion of flour

Other

Infant and young child feeding education and promotion of porridge and groundnut flours from 6-18 months

Primary outcomes

  1. Linear growth

    Time frame: 18 months

    Length for age Z score

Secondary outcomes

  1. Linear growth

    Time frame: 12 months

    Length for age Z score

  2. Prevalence of stunting

    Time frame: 12 and 18 months

    Prevalence of stunting (<-2 LAZ)

  3. Ponderal growth

    Time frame: 12 and 18 months

    Weight for age Z score

  4. Prevalence of underweight

    Time frame: 12 and 18 months

    Prevalence of underweight (<-2 WAZ)

  5. Concentration of urinary biomarker

    Time frame: 9, 12, 15, 18 months

    Concentration of aflatoxin M1 (AFM1) urinary biomarker

  6. Concentration of AF blood biomarker

    Time frame: 12 and 18 months

    Concentration of AF blood biomarker AF-alb

  7. Middle-upper-arm circumference (MUAC)

    Time frame: 12 and 18 months in full sample; 9, 12, 15, 18 months in sub-samples

    Middle-upper-arm circumference Z score

  8. Head circumference

    Time frame: 12 and 18 months in full sample; 9, 12, 15, 18 months in sub-samples

    Head-circumference-for-age Z score

Sponsors and collaborators

Lead sponsor

Cornell University

Other

Collaborators

  • The Nelson Mandela African Institution of Science and Technology
  • University of Maryland

Registry information

Official study title

Trial to Establish Causal Linkage Between Mycotoxin Exposure and Child Stunting

Acronym: MMT

Important dates

Study start
2019
Primary completion
2021
Study completion
2021
First posted
May 7, 2019
Registry last updated
Feb 7, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.